Cletus Adiyaga Wezena

Cletus Adiyaga Wezena

Auto-generated profile, based on publicly available information

Cletus Adiyaga Wezena

Department of Microbiology, Faculty of Biosciences, University for Development Studies, Tamale, Northern Region, Ghana

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
JDJulius T. Dongdem
Julius T. Dongdem
GHGideon Kofi Helegbe
Gideon Kofi Helegbe
KOKwame Opare-Asamoah
Kwame Opare-Asamoah
CWCletus A. Wezena
Cletus A. Wezena
AOAugustine Ocloo
Augustine Ocloo
Pain relief remains a major subject of inadequately met need of patients. Therapeutic agents designed to treat pain and inflammation so far have low to moderate efficiencies with significant untoward side effects. FAAH-1 has been proposed as a promising target for the discovery of drugs to treat pain and inflammation without significant adverse effects. FAAH-1 is the primary enzyme accountable for the degradation of AEA and related fatty acid amides. Studies have revealed that the simultaneous inhibition of COX and FAAH-1 activities produce greater pharmacological efficiency with significantly lowered toxicity and ulcerogenic activity. Recently, the metabolism of endocannabinoids by COX-2 was suggested to be differentially regulated by NSAIDs. We analysed the affinity of oleamide, arachidonamide and stearoylamide at the FAAH-1 in vitro and investigated the potency of selected NSAIDs on the hydrolysis of endocannabinoid-like molecules (oleamide, arachidonamide and stearoylamide) by FAAH-1 from rat liver. NSAIDs were initially screened at 500 μM after which those that exhibited greater potency were further analysed over a range of inhibitor concentrations. The substrate affinity of FAAH-1 obtained, increased in a rank order of oleamide < arachidonamide < stearoylamide with resultant Vmax values in a rank order of arachidonamide > oleamide > stearoylamide. The selected NSAIDs caused a concentration-dependent inhibition of FAAH-1 activity with sulindac, carprofen and meclofenamate exhibiting the greatest potency. Michaelis-Menten analysis suggested the mode of inhibition of FAAH-1 hydrolysis of both oleamide and arachidonamide by meclofenamate and indomethacin to be non-competitive in nature. Our data therefore suggest potential for study of these compounds as combined FAAH-1-COX inhibitors.

1 January 2024 in Advances in Pharmacological and Pharmaceutical Sciences
Verified
Journal Article
Open access
JDJulius T. Dongdem
Julius T. Dongdem
AEAxandrah E. Etornam
Axandrah E. Etornam
SBSolomon Beletaa
Solomon Beletaa
IAIssah Alidu
Issah Alidu
Hassan KoteyHassan Kotey
Hassan Kotey
CWCletus A. Wezena
Cletus A. Wezena
The discovery and characterization of the signal cascades of the β‐adrenergic receptors have made it possible to effectively target the receptors for drug development. β‐Adrenergic receptors are a class A rhodopsin type of G protein‐coupled receptors (GPCRs) that are stimulated mainly by catecholamines and therefore mediate diverse effects of the parasympathetic nervous system in eliciting “fight or flight” type responses. They are detectable in several human tissues where they control a plethora of physiological processes and therefore contribute to the pathogenesis of several disease conditions. Given the relevance of the β‐adrenergic receptor as a molecular target for many pathological conditions, this comprehensive review aims at providing an in‐depth exploration of the recent advancements in β3‐adrenergic receptor research. More importantly, we delve into the prospects of the β3‐adrenergic receptor as a therapeutic target across a variety of clinical domains.

24 August 2022 in Heliyon
Verified
Journal Article
Open access
JAJames Abugri
James Abugri
JAJoseph Ayariga
Joseph Ayariga
SSSamuel Sunyazi Sunwiale
Samuel Sunyazi Sunwiale
CWCletus Adiyaga Wezena
Cletus Adiyaga Wezena
JGJulien Agyemang Gyamfi
Julien Agyemang Gyamfi
BDBismarck Dinko
Bismarck Dinko
There is an unmet need to unearth alternative treatment options for malaria, wherein this quest is more pressing in recent times due to high morbidity and mortality data arising mostly from the endemic countries coupled with partial diversion of attention from the disease in view of the SARS-Cov-2 pandemic. Available therapeutic options for malaria have been severely threatened with the emergence of resistance to almost all the antimalarial drugs by the Plasmodium falciparum parasite in humans, which is a worrying situation. Artemisinin combination therapies (ACT) that have so far been the mainstay of malaria have encountered resistance by malaria parasite in South East Asia, which is regarded as a notorious ground zero for the emergence of resistance to antimalarial drugs. This review analyzes a few key druggable targets for the parasite and the potential of specific inhibitors to mitigate the emerging antimalarial drug resistance problem by providing a concise assessment of the essential proteins of the malaria parasite that could serve as targets. Moreover, this work provides a summary of the advances made in malaria parasite biology and the potential to leverage these findings for antimalarial drug production.